- Home
- NYXH vs MGNX Comparison
NYXH vs MGNX Comparison
Compare NYXH & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NYXH
- MGNX
- Stock Information
- Founded
- NYXH 2009
- MGNX 2000
- Country
- NYXH Belgium
- MGNX United States
- Employees
- NYXH N/A
- MGNX N/A
- Industry
- NYXH Medical/Dental Instruments
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- NYXH Health Care
- MGNX Health Care
- Exchange
- NYXH Nasdaq
- MGNX Nasdaq
- Market Cap
- NYXH 261.1M
- MGNX 257.3M
- IPO Year
- NYXH 2021
- MGNX 2013
- Fundamental
- Price
- NYXH $7.94
- MGNX $3.32
- Analyst Decision
- NYXH Strong Buy
- MGNX Hold
- Analyst Count
- NYXH 5
- MGNX 10
- Target Price
- NYXH $17.00
- MGNX $7.17
- AVG Volume (30 Days)
- NYXH 38.9K
- MGNX 471.3K
- Earning Date
- NYXH 11-06-2024
- MGNX 11-05-2024
- Dividend Yield
- NYXH N/A
- MGNX N/A
- EPS Growth
- NYXH N/A
- MGNX N/A
- EPS
- NYXH N/A
- MGNX N/A
- Revenue
- NYXH $5,668,079.00
- MGNX $141,329,000.00
- Revenue This Year
- NYXH $37.10
- MGNX $174.73
- Revenue Next Year
- NYXH $418.12
- MGNX N/A
- P/E Ratio
- NYXH N/A
- MGNX N/A
- Revenue Growth
- NYXH 32.65
- MGNX 16.68
- 52 Week Low
- NYXH $4.00
- MGNX $2.95
- 52 Week High
- NYXH $20.00
- MGNX $21.88
- Technical
- Relative Strength Index (RSI)
- NYXH 42.46
- MGNX 46.77
- Support Level
- NYXH $7.86
- MGNX $3.16
- Resistance Level
- NYXH $8.81
- MGNX $3.64
- Average True Range (ATR)
- NYXH 0.48
- MGNX 0.19
- MACD
- NYXH 0.06
- MGNX -0.00
- Stochastic Oscillator
- NYXH 43.87
- MGNX 37.70
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).